PMID- 15017433 OWN - NLM STAT- MEDLINE DCOM- 20041102 LR - 20230210 IS - 0893-3952 (Print) IS - 0893-3952 (Linking) VI - 17 IP - 5 DP - 2004 May TI - Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. PG - 588-96 AB - Endoscopic brush cytology is a promising surveillance technique for Barrett's esophagus. Ancillary markers are sought to increase the sensitivity of cytology and allow identification of patients at increased risk for disease progression. To determine if there are specific genetic changes in Barrett's esophagus with associated high-grade dysplasia/intramucosal adenocarcinoma compared to those without dysplasia, we performed fluorescence in situ hybridization (FISH) on cytologic specimens using probes to chromosomes and genomic regions previously described as altered in this disease. We studied archival brush cytology slides from 40 Barrett's esophagus patients: 21 with biopsy-proven high-grade dysplasia/carcinoma and 19 with no dysplasia and a minimum 5 years of negative follow-up. Centromeric enumeration probes (CEP) for chromosomes 6, 7, 11, and 12, and locus-specific probes (LSI) for 9p21 (p16 gene), and 17p13.1 (p53 gene) loci along with their corresponding CEP (9 and 17, respectively) were used in this study. A positive FISH result was defined as the presence of cells with >2 CEP signals or with a loss of the LSI signals relative to their corresponding CEP. p53 locus loss and/or aneusomy of chromosomes 6, 7, 11, and 12 abnormalities could be detected by FISH in routinely processed endoscopic brush cytology specimens from 95% of biopsy-positive cases with a specificity of 100%. Interestingly, all five cases with cytologic changes classified as indefinite for dysplasia from patients with a positive biopsy showed changes by FISH. Loss of the p16 locus was seen commonly in patients both with and without dysplasia/carcinoma. Selected biomarkers from this study merit further investigation to determine their potential to detect genetic changes in patients with Barrett's esophagus prior to the development of high-grade dysplasia. FAU - Fahmy, Mona AU - Fahmy M AD - Department of Anatomic and Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. FAU - Skacel, Marek AU - Skacel M FAU - Gramlich, Terry L AU - Gramlich TL FAU - Brainard, Jennifer A AU - Brainard JA FAU - Rice, Thomas W AU - Rice TW FAU - Goldblum, John R AU - Goldblum JR FAU - Connor, Jason T AU - Connor JT FAU - Casey, Graham AU - Casey G FAU - Legator, Mona S AU - Legator MS FAU - Tubbs, Raymond R AU - Tubbs RR FAU - Falk, Gary W AU - Falk GW LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Mod Pathol JT - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JID - 8806605 RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - 0 (Nucleic Acid Probes) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Barrett Esophagus/genetics/*pathology MH - Biopsy MH - *Chromosome Aberrations MH - Chromosomes, Human, Pair 11/genetics MH - Chromosomes, Human, Pair 12/genetics MH - Chromosomes, Human, Pair 17/genetics MH - Chromosomes, Human, Pair 6/genetics MH - Chromosomes, Human, Pair 7/genetics MH - Chromosomes, Human, Pair 9/genetics MH - Cyclin-Dependent Kinase Inhibitor p16/*genetics MH - Cytodiagnosis/methods MH - Esophagus/metabolism/pathology MH - Humans MH - In Situ Hybridization, Fluorescence/*methods MH - Nucleic Acid Probes/genetics MH - Sensitivity and Specificity MH - Tumor Suppressor Protein p53/*genetics EDAT- 2004/03/16 05:00 MHDA- 2004/11/04 09:00 CRDT- 2004/03/16 05:00 PHST- 2004/03/16 05:00 [pubmed] PHST- 2004/11/04 09:00 [medline] PHST- 2004/03/16 05:00 [entrez] AID - S0893-3952(22)04383-6 [pii] AID - 10.1038/modpathol.3800088 [doi] PST - ppublish SO - Mod Pathol. 2004 May;17(5):588-96. doi: 10.1038/modpathol.3800088.